SOCRA - Society of Clinical Research Associates Society of Clinical Research Associates Adverse Event Safety Reporting 1

Question 1

Which of the following criteria qualifies an adverse event as 'serious' (SAE) under ICH E6 GCP guidelines?

Accepted Answer

An adverse event resulting in death, hospitalization, persistent disability, or congenital anomaly

Answer

ICH E6 defines a serious adverse event as one that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or constitutes an important medical event requiring intervention to prevent one of these outcomes.

Question 2

Under 21 CFR 312.32, who bears primary responsibility for submitting IND safety reports to the FDA?

Accepted Answer

The sponsor of the investigational new drug application

Answer

The sponsor holds the IND and is therefore primarily responsible for submitting safety reports to the FDA under 21 CFR 312.32. Investigators report SAEs to the sponsor, who evaluates causality and expectedness before determining whether FDA notification is required.

Question 3

What is the required timeframe for submitting a non-expedited (periodic) IND safety report to the FDA?

Accepted Answer

Annually, within 60 days of the IND anniversary date

Answer

Annual IND safety reports (non-expedited) must be submitted to the FDA within 60 days of the anniversary of the IND going into effect. These reports provide a cumulative summary of adverse events that do not meet expedited reporting thresholds, unlike 7-day or 15-day reports for unexpected serious suspected adverse reactions.

Question 4

Which form is used in the United States for mandatory reporting of serious adverse events by investigators and manufacturers to the FDA?

Accepted Answer

MedWatch Form 3500A

Answer

The MedWatch Form 3500A is the FDA's mandatory reporting form for healthcare professionals, manufacturers, and distributors to report serious adverse events. The CIOMS I form is used for international submissions, FDA Form 1572 is the investigator statement of responsibilities, and ICH E2B is an electronic transmission standard.

Question 5

In adverse event causality assessment, what does a 'probable' relationship between an investigational product and an adverse event indicate?

Accepted Answer

A reasonable causal relationship exists and alternative explanations are unlikely, with the event improving on dechallenge

Answer

'Probable' causality means there is a plausible time relationship, alternative explanations are unlikely, and the event typically improves on dechallenge (withdrawal of the drug). It suggests a likely connection but does not reach the certainty of 'definite,' which also requires positive rechallenge or definitive confirmation.

(SOCRA) Society of Clinical Research Associates Practice Test

(SOCRA) Society of Clinical Research Associates Practice Test

SOCRA - Society of Clinical Research Associates Society of Clinical Research Associates Adverse Event Safety Reporting 1